在药物遗传学中实施预防性测试的好处和挑战:一个案例报告
1University of North Carolina at Wilmington, School of Nursing, Wilmington, North Carolina.
Journal of the American Association of Nurse Practitioners
|February 27, 2026
概括
预防性药物基因组学 (PGx) 测试使用遗传信息来指导药物决策,从反应性方法转向反应性方法. 这种个性化药物策略减少了药物不良反应,通过预防毒性和降低医疗保健成本,改善了患者的治疗结果.
科学领域:
- 药物基因组学 药物基因组学
- 遗传学 是一个遗传学.
- 临床药理学 临床药理学
背景情况:
- 药物基因组学 (PGx) 测试越来越多地从反应性 (药物不良反应后) 转向预防性策略.
- 目前的做法通常只在考虑特定药物或发生不良事件后进行PGx测试.
- 越来越多的运动倡导在开始药物治疗之前主动获取遗传信息.
研究的目的:
- 探索药物基因组学测试在临床环境中从反应性到预防性方法的转变.
- 通过患者病例研究来说明预防性PGx测试的好处.
- 确定阻碍预防性PGx.广泛实施的挑战.
主要方法:
- 文献综述和对药物基因组学实施当前趋势的综合分析.
- 案例研究分析,证明了预防性PGx在个性化治疗规划中的应用.
- 讨论广泛采用和潜在解决方案的障碍.
主要成果:
- 以药物代谢中的遗传变异为指导的预防性PGx测试可以个性化治疗计划.
- 关键的好处包括预防药物毒性,降低试错处方成本,提高患者参与度.
- 挑战包括医疗保健提供者的教育差距,数据隐私问题以及成本/报销问题,特别是在美国.
结论:
- 预防性PGx测试的广泛采用需要解决教育,隐私和财务障碍.
- 克服这些挑战对于实现个性化医学的全部潜力至关重要.
- 确保公平获得预防性PGx测试对于推进患者护理至关重要.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetics and Pharmacogenomics: Overview
74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Principles of Pharmacogenetics: Types of Genetic Variants
59
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
59
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54


